Inclusion Criteria:

- Diagnosis of acute myelogenous leukemia (except acute promyelocytic leukemia) in a
first complete remission (CR1) and meet the following criteria:

- Meets the definition of complete remission by morphologic criteria including <5%
blasts in a moderately cellular (> 20% cellularity) or cellular marrow.

- Complete remission (CR) was achieved after no more than 2 cycles of standard
induction chemotherapy. Early re-induction therapy based on residual disease on
a day 14 bone marrow (BM) will count as a 2nd cycle. Prior therapy with
demethylating agents (i.e. azacitidine) is allowed, but patients must have
attained CR after standard cytotoxic therapy (defined as absolute neutrophil
count (ANC) > 1000 cells/μL, platelets > 100 x 10^9/L)

- No more than 3 months have lapsed from attainment of CR1

- No acute myelogenous leukemia (AML) consolidation therapy administered prior to
enrollment

- Not a candidate for allogeneic stem cell transplantation

- ≥ 60 years of age

- Karnofsky performance status ≥ 70%

- Available related HLA haploidentical natural killer (NK) cell donor (sibling,
offspring, or offspring of an HLA identical sibling) by at least Class I serologic
typing at the A&B locus (donor age 18-75 years)

- At least 30 days since last dose of chemotherapy

- Adequate organ function within 14 days of enrollment defined as:

- Creatinine: ≤ 2.0 mg/dL

- Hepatic: aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT) <
5 x upper limit of institutional normal (ULN)

- Pulmonary: oxygen saturation ≥ 90% on room air

- Cardiac: left ventricular ejection fraction (LVEF) by echocardiogram (ECHO or
MUGA) ≥ 40%, no uncontrolled angina, uncontrolled atrial or ventricular
arrhythmias, or evidence of acute ischemia or active conduction system
abnormalities (rate controlled a-fib is not an exclusion)

- Ability to be off prednisone and other immunosuppressive drugs for at least 3 days
prior to the NK cell infusion (excluding preparative regimen pre-meds)

- Voluntary written consent

Exclusion Criteria:

- Biphenotypic acute leukemia

- New progressive pulmonary infiltrates on screening chest x-ray or chest Computed
Tomography scan that has not been evaluated with bronchoscopy (when feasible).
Infiltrates attributed to infection must be stable/improving (with associated
clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or
documented fungal infections).

- Uncontrolled bacterial, fungal, or viral infections including human immunodeficiency
virus (HIV) - chronic asymptomatic viral hepatitis is allowed

- Pleural effusion large enough to be detectable on chest x-ray

- Known hypersensitivity to one or more of the study agents

Donor Selection:

- Related donor (sibling, offspring, or offspring of an HLA identical sibling) 18-75
years of age

- At least 40 kilograms

- In general good health as determined by the medical provider

- Negative for hepatitis and HIV on donor viral screen

- HLA-haploidentical donor/recipient match by at least Class I serologic typing at the
A&B locus

- Not pregnant

- Voluntary written consent